NASDAQ:BBOT BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis $8.40 +0.13 (+1.57%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBOT alerts:Sign Up Key Stats Today's Range$8.15▼$8.4550-Day Range$8.06▼$10.4252-Week Range$8.00▼$14.87Volume60,715 shsAverage Volume326,668 shsMarket Capitalization$672.95 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingModerate Buy Company Overview BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need. BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development. Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here. Prospective investors and researchers should consult the company’s SEC filings, investor presentations and official disclosures for up-to-date details on its pipeline, management team and strategic priorities.AI Generated. May Contain Errors. Read More BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreBBOT MarketRank™: BridgeBio Oncology Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 46th out of 69 stocks in the financial services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBridgeBio Oncology Therapeutics has a consensus price target of $26.00, representing about 209.5% upside from its current price of $8.40.Amount of Analyst CoverageBridgeBio Oncology Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about BridgeBio Oncology Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BridgeBio Oncology Therapeutics are expected to decrease in the coming year, from ($2.19) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Oncology Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Oncology Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBridgeBio Oncology Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BBOT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Oncology Therapeutics does not currently pay a dividend.Dividend GrowthBridgeBio Oncology Therapeutics does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.32 News SentimentBridgeBio Oncology Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Financial Services companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Oncology Therapeutics' insider trading history. Receive BBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBOT Stock News HeadlinesBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026April 22, 2026 | globenewswire.comBBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive ChairmanApril 22, 2026 | globenewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 6 at 1:00 AM | American Alternative (Ad)BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026April 21, 2026 | globenewswire.comBridgeBio Oncology Therapeutics: Poised To Bank On The KRAS RevolutionApril 21, 2026 | seekingalpha.comBBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal AdenocarcinomaApril 20, 2026 | globenewswire.comBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 13, 2026 | markets.businessinsider.comBBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026March 18, 2026 | globenewswire.comSee More Headlines BBOT Stock Analysis - Frequently Asked Questions How have BBOT shares performed this year? BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the beginning of 2026. Since then, BBOT shares have decreased by 27.0% and is now trading at $8.40. How do I buy shares of BridgeBio Oncology Therapeutics? Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BBOT's financial health is in the Red zone, according to TradeSmith. BBOT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorFinancial Services Industry Investment Offices Sub-IndustryTrading Current SymbolNASDAQ:BBOT CIK1869105 Webbbotx.com Phone(857) 702-0377FaxN/AEmployeesN/AYear Founded2025Price Target and Rating Average Price Target for BridgeBio Oncology Therapeutics$26.00 High Price Target$29.00 Low Price Target$23.00 Potential Upside/Downside+209.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio12.34 Quick Ratio12.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book1.63Miscellaneous Outstanding Shares80,113,000Free FloatN/AMarket Cap$672.95 million OptionableN/A Beta0.22 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BBOT) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredThey’re buying gold before the announcementThe U.S. holds 8,133 tonnes of gold valued at a fraction of today's market price - and one executive order cou...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Oncology Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Oncology Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBOT Stock Alerts